Reminder: SAVA Shareholders Deadline for Securities Claims

Investors who have suffered losses in Cassava Sciences, Inc. (NASDAQ: SAVA) securities are reminded by Kessler Topaz Meltzer & Check, LLP of the upcoming deadline in the securities fraud class action lawsuit against the company. The lawsuit alleges that Cassava Sciences made false and misleading statements regarding its drug candidate, simufilam, for the treatment of Alzheimer’s disease.

According to the lawsuit, Cassava Sciences misled investors by claiming positive results from its Phase 2b clinical study of simufilam. The company allegedly failed to disclose that the study was flawed and included patients who did not meet the criteria for Alzheimer’s disease diagnosis. As a result, Cassava Sciences’ stock price was artificially inflated.

In response to these allegations, Cassava Sciences issued a statement maintaining the integrity of its study and defending the results. However, as the investigation progresses, more evidence is being brought to light that suggests otherwise.

Investors who purchased Cassava Sciences securities between February 2, 2021, and August 24, 2021, are encouraged to contact the law firm to discuss their legal rights before the October 26, 2021, deadline. It is crucial for investors to act quickly, as failure to meet this deadline may result in their exclusion from any potential recovery.

Kessler Topaz Meltzer & Check, LLP has a track record of success in securities fraud class action lawsuits, and they are dedicated to holding companies accountable for their misleading practices. Investors who believe they have been affected by Cassava Sciences’ alleged securities fraud should not hesitate to seek legal representation.

Overall, it is essential for investors to stay informed about any potential lawsuits regarding securities fraud involving companies in which they have invested. By taking proactive steps to protect their interests, investors can help hold companies accountable for their actions and seek compensation for any losses they may have incurred.